Christophe Fritsch

Global Head of Alternative Credit

About Christophe

Christophe Fritsch is Global Head of Alternative Credit and member of the AXA IM Alts Management Board.

AXA IM Alts is a global leader in alternative investments, with €184bn in assets under management across Real Estate, Infrastructure, Alternative Credit, Private Debt, Private Equity and Hedge Funds. 

As head of the Alternative Credit business, which employs more than 100 professionals in Europe and the US, he oversees the Portfolio Management of a performing and diversified range of alternative assets, covering the entire risk/return spectrum. This includes Leverages Loans and Private Debt, CLOs, Asset Backed Securities, Bank Capital Solutions Transactions, Insurance Linked Securities, Mortgages, among others.

Before this role, Christophe was Head of Fund Management at AXA IM Alts’ Structured Finance Department. Christophe had been in this role since 2014.He was one of the founding members who contributed to the development of the Structured Finance platform (renamed Alternative Credit platform in 2022), which is today one of the world’s largest managers of alternative credit assets.

Christophe joined AXA IM in 2000 working in Actuarial and Financial Engineering. In 2003, he joined the Structured Finance division, undertaking various roles in structuring, portfolio management, development, and negotiation of structured products. He has over 26 years of experience in the industry.


He graduated from ENSAE with a major in Stochastic Modelling, Statistics, Finance and Actuarial Science. He is a qualified actuary from IAF, the French Institute of Actuarial Science, and holds a Master’s degree in Mathematics and Economics from the University Panthéon-Sorbonne.

Investment Institute

Bringing together experts from across our research and investment teams to help you make more informed investment decisions.

Viewpoint CIO

High inflation and flat screens

  • by Chris Iggo
  • 02 December 2022 (3 min read)
Technology

Could an Alzheimer’s breakthrough herald a major new market for biotech?

  • by Peter Hughes , Cinney Zhang
  • 01 December 2022 (7 min read)
Annual Outlook

UK outlook – Navigating troubled waters

  • by Modupe Adegbembo
  • 01 December 2022 (7 min read)
Investment Institute

Get exclusive insights from our experts

Visit the institute